In summary, our research found that NSCLC patients with EGFR-sensitive mutations accompanied by high expression of PD-L1 or high TMB values may have a higher frequency of abnormal activation in the PI3K pathway. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.